Conquering epilepsies & brain disorders with courageous science
Science-driven and patient-focused, our mission is to develop medicines that transform the lives of patients with epilepsies and seizure-related disorders.
Our deep understanding of human genetics and cellular function enables us to translate discoveries into meaningful therapies for epilepsies and seizure-related disorders.
At Ovid, we seek to understand what matters most to individuals with rare diseases and their families. We are committed to address the challenges they face every day.
- Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
- Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
Each team member understands the difference between a drug and a medicine—one is a product, the other changes lives—and that's what brings us together as Ovidians.